Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.

Authors :: Savoy JM
Welch MA
Nasnas PE
Kantarjian H
Jabbour E
Source :: Therapeutic advances in hematology [Ther Adv Hematol] 2018 Nov 22; Vol. 9 (12), pp. 347-356. Date of Electronic Publication: 2018 Nov 22 (Print Publication: 2018).
Publication Year :: 2018
Abstract: Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.<br />Competing Interests: Conflict of interest statement: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2018.)